NCT06236789View on ClinicalTrials.gov

Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

Prostatic Neoplasm

Interventions

DRUG

Ifosfamide/mesna

Ifosfamide 2,500 mg/m2/day for 3 days every 3 weeks with mesna until disease progression

Trial Locations (1)

Unknown

RECRUITING

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Seoul

All Listed Sponsors

lead

Yonsei University

OTHER